Comparison of topical triomcinolone acetonide1/0% alone with combination therapy of topical retinoic acid 05/0% and triamcinolone acetonide1/0% in the treatmentofsymptomatic Geograpic tongue

Comparison of topical triomcinolone acetonide with combination therapy of topical retinoic acid and triamcinolone acetonide on Pain , Size and Burn in symptomatic Geographic tongue: A Randomized-Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211062464N6

Enrollment

Registered

2015-03-09

Start date

2012-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

symptomatic Geographic Tongue.

Interventions

Intervention 1: The method of intervention was randomized. Patients were divided into two groups A and B. The patients were randomly assigned to one of two treatment. In interventional group triamci

Treatment - Drugs

The method of intervention was randomized. Patients were divided into two groups A and B. The patients were randomly assigned to one of two treatment. In interventional group triamcinolone acetonide

In control group combined drug(retinoic acid 0.05% and triamcinolone acetonide 0.1% in an oral base) was prescribed. This drug prepared in the medicinal chemistry department of pharmacy school in Te

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:all the above 18-year-old patients with symptomatic geographic tongue who were able to use ointment; Exclusion criteria: history of systemic or topical corticosteroid use at least within a month before treatment? smokers? pregnant women ?those with any serious systemic disease that may interfere with the drug, such as diabetes; hypertension? heart disease ? neurological problems ? hepatitis ?renal disease ? chemotherapy and radiotherapy .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before treatment,10 days after treatment.1,2 month after treatment cessation. Method of measurement: Visual analog scale (VAS ).;Lesion size. Timepoint: Before treatment, 10 days after treatment,1,2 month after treatment cessation. Method of measurement: Ruler.;Burn. Timepoint: Before treatment,10 days after treatment.1,2,month after treatment cessation. Method of measurement: VAS scale.	—

Measure

Time frame

Pain. Timepoint: Before treatment,10 days after treatment.1,2 month after treatment cessation. Method of measurement: Visual analog scale (VAS ).;Lesion size. Timepoint: Before treatment, 10 days after treatment,1,2 month after treatment cessation. Method of measurement: Ruler.;Burn. Timepoint: Before treatment,10 days after treatment.1,2,month after treatment cessation. Method of measurement: VAS scale.

—

Secondary

Measure	Time frame
Recurrent of lesion. Timepoint: 1,2 month after treatment cessiation. Method of measurement: pain and burning) were measured and recorded according to VAS ,size with compare photography befor and after treatment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShamsoulmolouk Najafi, Faculty of Dentistry,

International campus, Faculty of Dentistry,Tehran University of Medical Sciences.

najafi_sh@tums.ac.ir+98 21 8802 5355

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026